Min Zhang

COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)

Ling Yin, Yunping Lu, Yang Song, 2020, International Journal of Antimicrobial Agents.

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

Stanley B. Cohen, A. Kivitz, R. Alten, 2020, BioDrugs.

Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.

Y. Chong, Xiangyong Li, Zhiliang Gao, 2015, International journal of clinical and experimental medicine.

Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.

Y. Chong, Xiangyong Li, Mingxing Huang, 2016, Clinics and research in hepatology and gastroenterology.

Effects of Hepatitis B Surface Antigen on Virus-specific and Global T Cells in Patients With Chronic HBV infection.

Y. Chong, E. Newell, Yang Cheng, 2020, Gastroenterology.

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

V. Tseluyko, R. Alten, S. Radominski, 2019, RMD Open.

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

A. Kivitz, R. Alten, S. Radominski, 2020, BioDrugs.